Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

HeartBeam (NASDAQ: BEAT) Management to Participate in March 2026 Investor and Industry Conferences 

Tipranks - Tipranks - Tue Mar 10, 11:14AM CDT

Austin, Texas, United States, March 9th, 2026, FinanceWire

Claim 70% Off TipRanks Premium

HeartBeam (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing advanced cardiac insights, announced that its management team will attend several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging. In addition, Eno, Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology’s annual scientific conference on March 28-30, where the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. 

To view the full press release, visit https://ibn.fm/tnwvK 

About HeartBeam, Inc. 

HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1) . The Company holds over 20 issued patents related to technology enablement.  

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Contact

IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com

If you want to submit your press release through TipRanks NewsWire, please go to the following link.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).